RegulatoryAug 4, 2026, 07:32 AM
Abeona Therapeutics' ZEVASKYN Receives CMS NTAP Status
AI Summary
Abeona Therapeutics Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for its gene therapy, ZEVASKYN. This designation, under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule, provides supplemental CMS reimbursement to support access to the innovative therapy. The company stated that NTAP status strengthens payor coverage and reinforces reimbursement for Medicare patients, recognizing ZEVASKYN’s meaningful clinical benefit.
Key Highlights
- CMS granted New Technology Add-On Payment (NTAP) status for ZEVASKYN.
- NTAP status is under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule.
- This provides supplemental CMS reimbursement above standard hospital payments for ZEVASKYN.
- NTAP status strengthens broad payor coverage and reinforces reimbursement for Medicare patients.
- ZEVASKYN is the first and only autologous cell sheet-based gene therapy for RDEB wounds.
- The designation recognizes ZEVASKYN’s clinical benefit and optimizes treatment center economics.
Price Impact
More from ABEO